Design of oral agents for the management of multiple sclerosis: Benefit and risk assessment for dimethyl fumarate

Drug Design, Development and Therapy

Volumn 8, Issue , 2014, Pages 897-908

  Nicholas, Jacqueline Ann ^a   Lee Boster, Aaron ^a   Imitola, Jaime ^a   O'Connell, Colleen ^a   Racke, Michael Karl ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

Dimethyl fumarate; Disease modifying therapy; Multiple sclerosis; Nrf2 pathway; Quality of life

Indexed keywords

FINGOLIMOD; FUMADERM; FUMARIC ACID DIMETHYL ESTER; GLATIRAMER; GLUTAMIC ACID; HEME OXYGENASE 1; INTERFERON; NATALIZUMAB; PLACEBO; TERIFLUNOMIDE; IMMUNOSUPPRESSIVE AGENT;

CLINICAL TRIAL (TOPIC); DRUG DESIGN; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; HUMAN; LYMPHOCYTE DIFFERENTIATION; MULTIPLE SCLEROSIS; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PHASE 3 CLINICAL TRIAL (TOPIC); PSORIASIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK BENEFIT ANALYSIS; TH1 CELL; TH17 CELL; ORAL DRUG ADMINISTRATION; RISK ASSESSMENT;

ADMINISTRATION, ORAL; DIMETHYL FUMARATE; DRUG DESIGN; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MULTIPLE SCLEROSIS; RISK ASSESSMENT;

EID: 84904063694     PISSN: None     EISSN: 11778881     Source Type: Journal    
DOI: 10.2147/DDDT.S50962     Document Type: Review

References (102)

1. Anderson DW, Ellenberg JH, Leventhal CM, et al. Revised estimate of the prevalence of multiple sclerosis in the United States. Ann Neurol. 1992;31(3):333-336.
2. Frohman EM, Racke MK, Raine CS. Multiple sclerosis - the plaque and its pathogenesis. N Engl J Med. 2006;354(9):942-955.
3. Arnason BG. Relevance of experimental allergic encephalomyelitis to multiple sclerosis. Neurol Clin. 1983;1(3):765-782.
4. Sadovnick AD, Ebers GC. Epidemiology of multiple sclerosis: a critical overview. Can J Neurol Sci. 1993;20(1):17-29.
5. [No authors listed]. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group. Neurology. 1993;43(4):655-661.
6. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular inter-feron beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol. 1996;39(3):285-294.
7. Johnson K P, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology. 1995;45(7):1268-1276.
8. Milleforini E, Gasperini C, Pozzilli C, et al. Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-month clinical and MRI outcome. J Neurol. 1997;244(3): 153-159.
9. Polman CH, O'Connor P W, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006;354(9):899-910.
10. Kappos L, Radue E W, O'Connor P, et al. A placebo-controlled trial of oral fngolimod in relapsing multiple sclerosis. N Engl J Med. 2010;362(5):387-401.
11. O'Connor P, Wolinsky JS, Confavreux C, et al. Randomized trial of oral terifunomide for relapsing multiple sclerosis. N Engl J Med. 2011;365(14):1293-1303.
12. Gold R, Kappos L, Arnold DL, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med. 2012;367(12):1098-1107.
13. Kleinschmidt-DeMasters BK, Tyler KL. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med. 2005;353(4): 369-374.
14. Langer-Gould A, Atlas S W, Green AJ, Bollen AW, Pelletier D. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med. 2005;353(4):375-381.
15. Van Assche G, Van Ranst M, Sciot R, et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N Engl J Med. 2005;353(4):362-368.
16. Altmeyer PJ, Matthes U, Pawlak F, et al. Antipsoriatic effect of fumaric acid derivatives. Results of a multicenter double-blind study in 100 patients. J Am Acad Dermatol. 1994;30(6):977-981.
17. Kappos L, Gold R, Miller DH, Haghikia A. Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet. 2009;373(9672):1340-1340.
18. Schimrigk S, Brune N, Hellwig K, et al. Oral fumaric acid esters for the treatment of active multiple sclerosis: an open-label, baseline-controlled pilot study. Eur J Neurol. 2006;13(6):604-610.
19. Ghoreschi K, Bruck J, Kellerer C, et al. Fumarates improve psoriasis and multiple sclerosis by inducing type II dendritic cells. J Exp Med. 2011;208(11):2291-2303.
20. Peng H, Guerau-de-Arellano M, Mehta VB, et al. Dimethyl fumarate inhibits dendritic cell maturation via nuclear factor kappaB (NF-kappaB) and extracellular signal-regulated kinase 1 and 2 (ERK1/2) and mitogen stress-activated kinase 1 (MSK1) signaling. J Biol Chem. 2012;287(33):28017-28026.
21. Gocke AR, Cravens PD, Ben LH, et al. T-bet regulates the fate of Th1 and Th17 lymphocytes in autoimmunity. J Immunol. 2007;178(3): 1341-1348.
22. Lovett-Racke AE, Rocchini AE, Choy J, et al. Silencing T-bet defnes a critical role in the differentiation of autoreactive T lymphocytes. Immunity. 2004;21(5):719-731.
23. Yang Y, Weiner J, Liu Y, et al. T-bet is essential for encephalitogenicity of both Th1 and Th17 cells. J Exp Med. 2009;206(7):1549-1564.
24. McDonald AH, Swanborg RH. Antigen-specific inhibition of immune interferon production by suppressor cells of autoimmune encephalomyelitis. J Immunol. 1988;140(4):1132-1138.
25. Ando DG, Clayton J, Kono D, Urban JL, Sercarz EE. Encephalitogenic T cells in the B10.PL model of experimental allergic encephalomyelitis (EAE) are of the Th-1 lymphokine subtype. Cell Immunol. 1989;124(1): 132-143.
26. Waldburger KE, Hastings RC, Schaub RG, Goldman SJ, Leonard JP. Adoptive transfer of experimental allergic encephalomyelitis after in vitro treatment with recombinant murine interleukin-12. Preferential expansion of interferon-gamma-producing cells and increased expression of macrophage-associated inducible nitric oxide synthase as immuno-modulatory mechanisms. Am J Pathol. 1996;148(2):375-382.
27. Yura M, Takahashi I, Serada M, et al. Role of MOG-stimulated Th1 type "light up" (GFP+) CD4+ T cells for the development of experimental autoimmune encephalomyelitis (EAE). J Autoimmun. 2001;17(1):17-25.
28. Olsson T, Zhi W W, Hojeberg B, et al. Autoreactive T lymphocytes in multiple sclerosis determined by antigen-induced secretion of interferon-gamma. J Clin Invest. 1990;86(3):981-985.
29. Sun JB, Olsson T, Wang WZ, et al. Autoreactive T and B cells responding to myelin proteolipid protein in multiple sclerosis and controls. Eur J Immunol. 1991;21(6):1461-1468.
30. Voskuhl RR, Martin R, Bergman C, Dalal M, Ruddle NH, McFarland HF. T helper 1 (Th1) functional phenotype of human myelin basic protein-specifc T lymphocytes. Autoimmunity. 1993;15(2):137-143.
31. Pelfrey CM, Rudick RA, Cotleur AC, Lee JC, Tary-Lehmann M, Lehmann PV. Quantifcation of self-recognition in multiple sclerosis by single-cell analysis of cytokine production. J Immunol. 2000;165(3):1641-1651.
32. Ferber IA, Brocke S, Taylor-Edwards C, et al. Mice with a disrupted IFN-gamma gene are susceptible to the induction of experimental autoimmune encephalomyelitis (EAE). J Immunol. 1996;156(1):5-7.
33. Willenborg DO, Fordham S, Bernard CC, Cowden WB, Ramshaw IA. IFN-gamma plays a critical down-regulatory role in the induction and effector phase of myelin oligodendrocyte glycoprotein-induced autoimmune encephalomyelitis. J Immunol. 1996;157(8):3223-3227.
34. Heremans H, Dillen C, Groenen M, Martens E, Billiau A. Chronic relapsing experimental autoimmune encephalomyelitis (CREAE) in mice: enhancement by monoclonal antibodies against interferon-gamma. Eur J Immunol. 1996;26(10):2393-2398.
35. Bielekova B, Goodwin B, Richert N, et al. Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand. Nat Med. 2000;6(10):1167-1175.
36. Lublin FD, Knobler RL, Kalman B, et al. Monoclonal anti-gamma interferon antibodies enhance experimental allergic encephalomyelitis. Autoimmunity. 1993;16(4):267-274.
37. Chu CQ, Wittmer S, Dalton DK. Failure to suppress the expansion of the activated CD4 T cell population in interferon gamma-defcient mice leads to exacerbation of experimental autoimmune encephalomyelitis. J Exp Med. 2000;192(1):123-128.
38. Racke MK, Burnett D, Pak SH, et al. Retinoid treatment of experimental allergic encephalomyelitis. IL-4 production correlates with improved disease course. J Immunol. 1995;154(1):450-458.
39. Racke MK, Bonomo A, Scott DE, et al. Cytokine-induced immune deviation as a therapy for infammatory autoimmune disease. J Exp Med. 1994;180(5):1961-1966.
40. Chitnis T, Najafan N, Benou C, et al. Effect of targeted disruption of STAT4 and STAT6 on the induction of experimental autoimmune encephalomyelitis. J Clin Invest. 2001;108(5):739-747.
41. Bettelli E, Sullivan B, Szabo SJ, Sobel RA, Glimcher LH, Kuchroo VK. Loss of T-bet, but not STAT1, prevents the development of experimental autoimmune encephalomyelitis. J Exp Med. 2004;200(1):79-87.
42. Nath N, Prasad R, Giri S, Singh AK, Singh I. T-bet is essential for the progression of experimental autoimmune encephalomyelitis. Immunology. 2006;118(3):384-391.
43. Langrish CL, Chen Y, Blumenschein WM, et al. IL-23 drives a pathogenic T cell population that induces autoimmune infammation. J Exp Med. 2005;201(2):233-240.
44. Lock C, Hermans G, Pedotti R, et al. Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nat Med. 2002;8(5):500-508.
45. Lees JR, Iwakura Y, Russell JH. Host T cells are the main producers of IL-17 within the central nervous system during initiation of experimental autoimmune encephalomyelitis induced by adoptive transfer of Th1 cell lines. J Immunol. 2008;180(12):8066-8072.
46. Komiyama Y, Nakae S, Matsuki T, et al. IL-17 plays an important role in the development of experimental autoimmune encephalomyelitis. J Immunol. 2006;177(1):566-573.
47. Haak S, Croxford AL, Kreymborg K, et al. IL-17A and IL-17F do not contribute vitally to autoimmune neuro-infammation in mice. J Clin Invest. 2009;119(1):61-69.
48. de Jong R, Bezemer AC, Zomerdijk T P, van de Pouw-Kraan T, Ottenhoff TH, Nibbering PH. Selective stimulation of T helper 2 cytokine responses by the anti-psoriasis agent monomethylfumarate. Eur J Immunol. 1996;26(9):2067-2074.
49. Ghoreschi K, Mrowietz U, Rocken M. A molecule solves psoriasis? Systemic therapies for psoriasis inducing interleukin 4 and Th2 responses. J Mol Med (Berl). 2003;81(8):471-480.
50. Loewe R, Pillinger M, de Martin R, et al. Dimethylfumarate inhibits tumor-necrosis-factor-induced CD62E expression in an NF-kappa B-dependent manner. J Invest Dermatol. 2001;117(6): 1363-1368.
51. Schilling S, Goelz S, Linker R, Luehder F, Gold R. Fumaric acid esters are effective in chronic experimental autoimmune encephalomyelitis and suppress macrophage infltration. Clin Exp Immunol. 2006;145(1): 101-107.
52. Linker RA, Lee DH, Ryan S, et al. Fumaric acid esters exert neuroprotective effects in neuroinfammation via activation of the Nrf2 antioxidant pathway. Brain. 2011;134 Pt 3:678-692.
53. Chen H, Assmann JC, Krenz A, et al. Hydroxycarboxylic acid receptor 2 mediates dimethyl fumarate's protective effect in EAE. J Clin Invest. 2014;124(5):2188-2192.
54. Milenkovic M, Arsenovic-Ranin N, Vucicevic D, Bufan B, Jancic I, Stojic-Vukanic Z. Benefcial effects of dimethyl fumarate on experimental autoimmune myocarditis. Arch Med Res. 2008;39(7):639-646.
55. Sean RD, Korner H, Strickland DH, Lemckert FA, Pollard JD, Sedgwick JD. Challenging cytokine redundancy: infammatory cell movement and clinical course of experimental autoimmune encephalomyelitis are normal in lymphotoxin-defcient, but not tumor necrosis factor-defcient, mice. J Exp Med. 1998;187(9):1517-1528.
56. Kroenke MA, Carlson TJ, Andjelkovic AV, Segal BM. IL-12- and IL-23-modulated T cells induce distinct types of EAE based on histology, CNS chemokine profle, and response to cytokine inhibition. J Exp Med. 2008;205(7):1535-1541.
57. Johnson JA, Johnson DA, Kraft AD, et al. The Nrf2-ARE pathway: an indicator and modulator of oxidative stress in neurodegeneration. Ann N Y Acad Sci. 2008;1147:61-69.
58. Schreibelt G, van Horssen J, van Rossum S, Dijkstra CD, Drukarch B, de Vries HE. Therapeutic potential and biological role of endogenous antioxidant enzymes in multiple sclerosis pathology. Brain Res Rev. 2007;56(2):322-330.
59. van Muiswinkel FL, Kuiperij HB. The Nrf2-ARE signalling pathway: promising drug target to combat oxidative stress in neurodegen-erative disorders. Curr Drug Targets CNS Neurol Disord. 2005;4(3): 267-281.
60. Franco R, Schoneveld OJ, Pappa A, Panayiotidis MI. The central role of glutathione in the pathophysiology of human diseases. Arch Physiol Biochem. 2007;113(4-5):234-258.
61. Wu G, Fang YZ, Yang S, Lupton JR, Turner ND. Glutathione metabolism and its implications for health. J Nutr. 2004;134(3):489-492.
62. Kapturczak MH, Wasserfall C, Brusko T, et al. Heme oxygenase-1 modulates early infammatory responses: evidence from the heme oxygenase-1-defcient mouse. Am J Pathol. 2004;165(3):1045-1053.
63. Hu CM, Lin HH, Chiang MT, Chang P F, Chau LY. Systemic expression of heme oxygenase-1 ameliorates type 1 diabetes in NOD mice. Diabetes. 2007;56(5):1240-1247.
64. Benallaoua M, Francois M, Batteux F, et al. Pharmacologic induction of heme oxygenase 1 reduces acute infammatory arthritis in mice. Arthritis Rheum. 2007;56(8):2585-2594.
65. Takeda Y, Takeno M, Iwasaki M, et al. Chemical induction of HO-1 suppresses lupus nephritis by reducing local iNOS expression and synthesis of anti-dsDNA antibody. Clin Exp Immunol. 2004;138(2):237-244.
66. Rueda B, Oliver J, Robledo G, et al. HO-1 promoter polymorphism associated with rheumatoid arthritis. Arthritis Rheum. 2007;56(12): 3953-3958.
67. Gilgun-Sherki Y, Melamed E, Offen D. The role of oxidative stress in the pathogenesis of multiple sclerosis: the need for effective antioxidant therapy. J Neurol. 2004;251(3):261-268.
68. Liu Y, Liu J, Tetzlaff W, Paty DW, Cynader MS. Biliverdin reductase, a major physiologic cytoprotectant, suppresses experimental autoimmune encephalomyelitis. Free Radic Biol Med. 2006;40(6):960-967.
69. Tajouri L, Mellick AS, Ashton KJ, et al. Quantitative and qualitative changes in gene expression patterns characterize the activity of plaques in multiple sclerosis. Brain Res Mol Brain Res. 2003;119(2):170-183.
70. Calabrese V, Scapagnini G, Ravagna A, et al. Disruption of thiol homeostasis and nitrosative stress in the cerebrospinal fuid of patients with active multiple sclerosis: evidence for a protective role of acetylcarnitine. Neurochem Res. 2003;28(9):1321-1328.
71. Calvani M, Arrigoni-Martelli E. Attenuation by acetyl-L-carnitine of neurological damage and biochemical derangement following brain ischemia and reperfusion. Int J Tissue React. 1999;21(1):1-6.
72. Guy J, Ellis EA, Hope GM, Rao NA. Antioxidant enzymes reduce loss of blood-brain barrier integrity in experimental optic neuritis. Arch Ophthalmol. 1989;107(9):1359-1363.
73. Liu Y, Zhu B, Luo L, Li P, Paty DW, Cynader MS. Heme oxygenase-1 plays an important protective role in experimental autoimmune encephalomyelitis. Neuroreport. 2001;12(9):1841-1845.
74. Mehindate K, Sahlas DJ, Frankel D, et al. Proinfammatory cytokines promote glial heme oxygenase-1 expression and mitochondrial iron deposition: implications for multiple sclerosis. J Neurochem. 2001;77(5):1386-1395.
75. Chora AA, Fontoura P, Cunha A, et al. Heme oxygenase-1 and carbon monoxide suppress autoimmune neuroinfammation. J Clin Invest. 2007;117(2):438-447.
76. Kalinin S, Polak PE, Lin SX, et al. Dimethyl fumarate regulates histone deacetylase expression in astrocytes. J Neuroimmunol. 2013;263(1-2): 13-19.
77. Pitt D, Werner P, Raine CS. Glutamate excitotoxicity in a model of multiple sclerosis. Nat Med. 2000;6(1):67-70.
78. Smith T, Groom A, Zhu B, Turski L. Autoimmune encephalomyelitis ameliorated by AMPA antagonists. Nat Med. 2000;6(1):62-66.
79. Kanwar JR, Kanwar RK, Krissansen GW. Simultaneous neuroprotection and blockade of infammation reverses autoimmune encephalomyelitis. Brain. 2004;127 Pt 6:1313-1331.
80. Werner P, Pitt D, Raine CS. Multiple sclerosis: altered glutamate homeostasis in lesions correlates with oligodendrocyte and axonal damage. Ann Neurol. 2001;50(2):169-180.
81. Srinivasan R, Sailasuta N, Hurd R, Nelson S, Pelletier D. Evidence of elevated glutamate in multiple sclerosis using magnetic resonance spectroscopy at 3 T. Brain. 2005;128 Pt 5:1016-1025.
82. Lukashev M, Zeng W, Goelz S, et al. Activation of Nrf2 and modulation of disease progression in EAE models by BG00012 (dimethyl fumarate) suggests a novel mechanism of action combining anti-infammatory and neuroprotective modalities. Mult Scler. 2007;13 Suppl:S149-S149.
83. Fox RJ, Miller DH, Phillips JT, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med. 2012;367(12):1087-1097.
84. Tecfdera® Full prescribing information. Dimethyl fumarate package insert. Research Triangle Park, NC, USA: Biogen Idec; 2013. Available from: http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=665d7e74-036c-5f68-5b67-ab84b9b49151. Accessed June 9, 2014.
85. Sweetser MT, Dawson KT, Bozic C. Manufacturer's response to case reports of PML. N Engl J Med. 2013;368(17):1659-1661.
86. Ermis U, Weis J, Schulz JB. PML in a patient treated with fumaric acid. N Engl J Med. 2013;368(17):1657-1658.
87. van Oosten B, Killestein J, Barkhof F, Polman CH, Wattjes M P. PML in a patient treated with dimethyl fumarate from a compounding pharmacy. N Engl J Med. 2013;368(17):1658-1659.
88. Hutchinson M, Fox RJ, Havrdova E, et al. Effcacy and safety of BG-12 (dimethyl fumarate) and other disease-modifying therapies for the treatment of relapsing-remitting multiple sclerosis: a systematic review and mixed treatment comparison. Curr Med Res Opin. 2014;30(4): 613-627.
89. Ratchford JN, Costello K, Reich DS, Calabresi PA. Varicella-zoster virus encephalitis and vasculopathy in a patient treated with fngolimod. Neurology. 2012;79(19):2002-2004.
90. Uccelli A, Ginocchio F, Mancardi GL, Bassetti M. Primary varicella zoster infection associated with fngolimod treatment. Neurology. 2011;76(11):1023-1024.
91. Nicholas JA, Racke MK, Imitola J, Boster AL. First-line natalizumab in multiple sclerosis: rationale, patient selection, benefts and risks. Ther Adv Chronic Dis. 2014;5(2):62-68.
92. Kappos L, Radue E W, O'Connor P, et al. A placebo-controlled trial of oral fngolimod in relapsing multiple sclerosis. N Engl J Med. 2010;362(5):387-401.
93. Coyle PK. Multiple sclerosis in pregnancy. Continuum (Minneap Minn). 2014;20(1 Neurology of Pregnancy):42-59.
94. O'Connor P, Wolinsky JS, Confavreux C, et al. Randomized trial of oral terifunomide for relapsing multiple sclerosis. N Engl J Med. 2011;365(14):1293-1303.
95. Polman CH, Uitdehaag BM. New and emerging treatment options for multiple sclerosis. Lancet Neurol. 2003;2(9):563-566.
96. Aubagio® (terifunomide) package insert. Cambridge, MA, USA: Genzyme Corporation; 2012. Available from: http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4650d12c-b9c8-4525-b07f-a2d773eca155. Accessed June 9, 2014.
97. Miller A, Dishon S. Health-related quality of life in multiple sclerosis: the impact of disability, gender and employment status. Qual Life Res. 2006;15(2):259-271.
98. Rudick RA, Miller D, Clough JD, Gragg LA, Farmer RG. Quality of life in multiple sclerosis. Comparison with infammatory bowel disease and rheumatoid arthritis. Arch Neurol. 1992;49(12): 1237-1242.
99. Kita M, Fox RJ, Gold R, et al. Effect of BG-12(DMF) on quality of life in patients with MS. Presented at the Consortium of Multiple Sclerosis Centers and Americas Committee for Treatment and Research in Multiple Sclerosis 18th Annual Meeting, Orlando, FL, USA, May 29 to June 1, 2013.
100. Kappos L, Gold R, Arnold DL, et al. Quality of life outcomes with BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: the DEFINE study. Mult Scler. 2014;20(2): 243-252.
101. Kita M, Fox RJ, Phillips JT, et al. Effects of BG-12 (dimethyl fumarate) on health-related quality of life in patients with relapsing-remitting multiple sclerosis: fndings from the CONFIRM study. Mult Scler. 2014;20(2):253-257.
102. Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis:2005 revisions to the "McDonald Criteria." Ann Neurol. 2005;58(6):840-846.